Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene + Abemaciclib vs Fulvestrant + Abemaciclib in ER+/HER2- Breast Cancer with ESR1 Mutation
NCT05696626Phase 3Recruiting
- Sponsor
- LeonaBio
- Start
- Oct 2023
- Primary completion
- Apr 2027
- Modality
- Orthosteric Ligands
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of lasofoxifene in breast cancer (2 arms), sponsored by LeonaBio. Primary endpoint: Progression-Free Survival at 3 years. Started Oct 2023; status: recruiting.
02
Drugs
lasofoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05696626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05696626.